^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Myelodysplastic Syndrome
    Drug:decitabine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    DACOGEN is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS)...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Guidelines are based on extensive evaluation of the reviewed risk-based data and indicate current approaches for managing patients with MDS. Five drugs approved by the FDA for treating specific subtypes of MDS include lenalidomide for patients with del(5q) cytogenetic abnormalities; AzaC and decitabine for treating higher-risk or non-responsive patients...
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Adv Ther
    Title:

    Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study

    Excerpt:
    This open-label, phase 3b study was conducted...132 patients received decitabine treatment...A total 35 (26.5%) patients achieved an ORR (CR + PR + mCR) during the study: CR in 13 patients (9.8%) and mCR in 22 patients...Decitabine, at the doses studied, was efficacious for the treatment of MDS in Chinese patients.
    DOI:
    10.1007/s12325-015-0263-8
    Trial ID:
    NCT01751867